Among secondary outcomes, the risk of acute pancreatitis was higher (HR 1.068, 95% CI 1.023–1.114), whereas chronic pancreatitis (HR 0.933, 95% CI 0.867–1.005) and pancreatic cancer (HR 0.953, 95% CI 0.880–1.033) did not differ significantly from Non–GLP-1 RA Users (Supplementary Table 5). Here, GLP1R is linked to familial pancreatic carcinoma.